An interventional study of Vibrotactile coordinated reset (vCR) in Parkinson Disease, sponsored by Stanford University. Not yet recruiting. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2024-09-05.
Sponsored by Stanford University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Parkinson Disease by Stanford University — 10 open to participants now, 10 under way, none of them phase 3. Parkinson Disease · Stanford University.
Among the 19 studies in Parkinson Disease by Stanford University, this one is the 19th largest by planned enrollment, is one of 6 that started in 2025, is one of 15 with no phase, and was the 15th registered.
4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.
Browse Parkinson Disease studies →10 of the 19 studies in Parkinson Disease by Stanford University are open now, in 1 country. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 18+ · Healthy volunteers
Stanford University · Sites in United States
Ages 40–80 · Healthy volunteers
Stanford University · Sites in United States
Ages 21+
Stanford University · Sites in United States
Ages 35–92
By country, each count listing its studies:
Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 6 started in 2025.
This study's planned enrollment of 5 is below the median of 40 across 3,360 interventional studies indexed under Parkinson Disease.
Median enrollment 20 across the 19 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 425 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
9 of the studies in Parkinson Disease by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05558189Stanford UniversityVibrotactile Coordinated Reset for the Treatment of Post Surgery Refractory Parkinson's Disease Patients | 2026-11-21 |
| NCT06029686Stanford UniversityVibrotactile Coordinated Reset for Parkinson's Patients of a More Variable Population | 2026-12 |
| NCT06028477Stanford UniversityVibrotactile Coordinated Reset in Parkinson's Disease - Proof of Concept Study | 2026-12-30 |
| NCT06559098Stanford UniversityVibrotactile Coordinated Reset (vCR) for the Treatment of Advanced Parkinson's Disease Patients Who Have Previously Received vCR Stimulation | 2027-01 |
| NCT06583005Stanford UniversityVibrotactile Coordinated Reset for Parkinsons Patients Who Are on Dopaminergic Medication | 2027-05-15 |
Add all 9 to your calendar (.ics) → With an account.
Among the 19 studies in Parkinson Disease by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to test the efficacy of vibrotactile coordinated reset(vCR) stimulation on human subject participants with advanced stage Parkinson's Disease who have previously received vCR therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients who were previously enrolled in a vibrotactile study meant to reduce symptoms associated with Parkinson's disease will be enrolled in the study and will be asked to stimulate with the Stanford Coordinated Reset(CR) glove in sessions that last 2 hours. Sessions may be daily or a few times weekly depending on the needs of the patient.
Device: Vibrotactile coordinated reset (vCR)
Vibrotactile Coordinated Reset delivers vibratory stimulation to the fingertips of each hand. A specific pattern of vibration to each fingertip is delivered which theoretically disrupts abnormal synchrony in the brain
Also known as: Stanford Coordinated Reset Glove
Movement Disorders Society Unified Parkinson's Disease Rating Scale Part 3 (MDS-UPDRS III) off medication
This scale measures motor ability within Parkinson's patients. For part 3, the scales minimum values is 0 and max value is 132. Higher scores indicate more impaired motor ability, while lower scores indicate less impaired motor ability. A score of 0 indicates no motor impairment.
Time frame: Baseline, 3Months,6 Months, 9 Months 12 Months, 18 Months, 24 Months
Levodopa equivalent daily dose (LEDD) daily change from baseline to 24 months
LEDD is calculated as a daily sum of levodopa in each Parkinson's medication
Time frame: 24 months
Parkinson's disease quality of life questionnaire-39 (PDQ-39)
The PD Quality of Life Questionnaire-39 (PDQ-39) is a self-report questionnaire that examines health related difficulties specific to PD in eight quality of life categories within the last month. Items are grouped into eight scales that are scored by expressing summed item scores as a percentage score ranging between 0 and 100, with higher % indicating more health problems.
Time frame: 24 months
Freezing of Gait Questionnaire (FOG) change
The Freezing of Gait questionnaire (FOG) assesses severity unrelated to falls in patients with Parkinson's Disease (PD), FOG frequency, disturbances in gait, and relationship to clinical features conceptually associated with gait and motor aspects (e.g., turning). The FOG is comprised of 6 questions measured on a 0 to 4 scale (where 0 is normal and 4 represents severe abnormalities). The scores are summed together with 0 representing the best possible score and 24 representing the worst possible score.
Time frame: 24 months
Movement disorders unified Parkinson's rating scale (MDS-UPDRS) part 1 change
The MDS-UPDRS part 1 focuses on non-motor symptoms, such as dementia, depression, and psychosis. The total summed score ranges from 0-52 with higher scores indicating increased non-motor impairment.
Time frame: 24 months
Movement disorders unified Parkinson's rating scale (MDS-UPDRS) part 2
The MDS-UPDRS part 2 focuses on the patient's ability to perform daily motor activities including dressing, grooming, and using utensils. The total summed score ranges from 0-52 with higher scores indicating increased daily motor impairment
Time frame: 24 months
Movement disorders unified Parkinson's rating scale (MDS-UPDRS) part 4 change
The MDS-UPDRS 4 focuses on Measures the complications of treatment, e.g. dyskinesias and motor fluctuations. The total summed score ranges from 0-24 with higher scores indicating increased motor complications.
Time frame: 24 months
Communicative Participation Item Bank (CPIB; Short Form)
The CPIB is a questionnaire that measures speech complications. The questionnaire is scored from 0 to 30, with a higher score indicating increased speech difficulties.
Time frame: 24 months
Voice Handicap Index (VHI-10)
This questionnaire can be filled out by patients and assesses the impact that voice problems and limitations have on the individual's overall daily function. Questionnaire is scored from 0 to 40, with a higher score indicating increased speech difficulties.
Time frame: 24 months
Spontaneous Electroencephalography beta band power change
Patients will be recorded while receiving vibrotactile stimulation. The Beta Band (13-30Hz) power spectral density (PSD) will be of interest. The units of the power spectral density are micro-Volts-squared per Hz. Increases in Beta band PSD are associated with motor impairment in Parkinson's disease, while decreases in the beta band are associated with motor improvement.
Time frame: 24 months
Parkinson's disease cognitive functional rating scale (PD-CFRS)
The PD-CFRS capture subjective daily functional cognitive decline among patients with Parkinson's disease over the past 2 weeks. The scale ranges from 0 to 24, with higher scores indicative of cognitive decline.
Time frame: 24 months
Device calibration
Participants will be assessed for their perceptive threshold of vibration, or the lowest vibration amplitude perceived. This is determined by adjusting the amplitude of the experimental device.
Time frame: 24 months
No study locations are listed for this record.
Start is estimated for Jan 2025; primary completion for Jan 2027, 24 months later.
Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's planned 24 months is close to that.
Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.